BioSpace News Archive

Crucial life-saving initiative led by Dr. Steven Quay for clinical trials on the safety and efficacy of a combination of FDA-approved drugs (nebulized H eparin-N-acetylcysteine in C O VID-19 P atients by E valuation of pulmonary function ( HOPE ))

CHASE Clinical Trial. On September 23, 2019, the Company announced findings from the pre-specified interim review of its ongoing CHASE clinical trial.

Sight Sciences, Inc., a growth-stage medical device company focused on transforming the treatment of glaucoma and dry eye disease, today announced that a review of the history of canal surgery in glaucoma, by Jaime Dickerson ,

EUA Application Follows Completion of Test Validation with Patient Samples by Physician-Scientists at UC San Diego

Avive Solutions, Inc, a developer of a next-generation Automated External Defibrillator and innovative cardiac arrest response solutions, was selected to present a study on a novel machine-learning algorithm for arrhythmia classification via a podium presentation at the American College of Cardiology Conference 2020.

Five Local Charities Selected in New Jersey and Washington, D.C. Areas by Otsuka America Pharmaceutical, Inc., the Sozosei Foundation has committed $500,000 in donations to five local charities in central New Jersey and Washington, D.C. areas to support those impacted by the Covid-19 Pandemic. The charities selected focus on an array of critical services such as providing meals and h

Promethera ® Announces Changes in Management Team

Aptorum Group Limited announced that it is initiating an additional research and development project targeting the coronavirus group and has completed initial screening under the Smart-ACT™ platform, a repurposed and new drug discovery platform, to select, out of more than 2,600 approved small drug molecules, at least 3 potential candidates for further preclinical investigation against the new coronavirus disease, COVID-19.

NDA submission based on previous pivotal trial data and a phase 2 study in Japan in patients with certain relapsed/refractory B-cell lymphomas

Kyros Law Offices is alerting investors of Valeant Pharmaceuticals (NYSE: VRX), now Bausch Health Companies (NYSE: BHC) that it is filing legal claims against the company on behalf of investors.